Related Experiment Video
Updated: May 16, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Prevention of contrast-induced nephropathy in STEMI patients undergoing primary percutaneous coronary intervention: a
Sarah Victoria Ekeløf Busch1, Svend Eggert Jensen, Jacob Rosenberg
1Centre for Perioperative Optimization, Department of Surgery, Herlev Hospital, University of Copenhagen, Herlev, Denmark. sarahekeloef@gmail.com
Insights
Preventing contrast-induced nephropathy (CIN) in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention requires further research. Hydration and brain natriuretic peptide show promise, while N-acetylcysteine had mixed results.
Area of Science:
- Cardiology
- Nephrology
- Interventional Cardiology
Background:
- Contrast-induced nephropathy (CIN) is a significant complication of cardiac catheterization, particularly in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).
- CIN increases the risk of adverse cardiac events, mortality, and renal dysfunction.
- Currently, no universally accepted strategy exists for CIN prevention in this high-risk acute setting.
Purpose of the Study:
- To systematically evaluate existing prophylactic strategies for CIN in STEMI patients treated with primary PCI.
- To identify effective interventions for reducing CIN incidence in this vulnerable patient population.
Main Methods:
- A systematic literature search was conducted in PubMed and EMBASE.
- Nine randomized clinical trials were included, investigating N-acetylcysteine, hydration regimens, recombinant human brain natriuretic peptide, and different contrast agents.
Main Results:
- Recombinant human brain natriuretic peptide and hydration regimens demonstrated significant reductions in CIN incidence.
- N-acetylcysteine showed a significant reduction in CIN in only one of six studies.
- Iso-osmolar contrast agents were not proven superior to low-osmolar agents in preventing CIN.
Conclusions:
- Preliminary evidence suggests potential benefits from hydration and recombinant human brain natriuretic peptide for CIN prevention.
- Further research is necessary to establish definitive, evidence-based recommendations for routine CIN prophylaxis in primary PCI for STEMI.
- The role of N-acetylcysteine and contrast agent choice requires additional investigation.
Objective:
To evaluate the current prophylactic strategies against CIN in patients with STEMI treated by primary percutaneous coronary intervention.
Background:
Contrast-induced nephropathy (CIN) is the third leading course of acute renal failure and a recognized complication to cardiac catheterization. CIN is associated with increased risk of cardiac adverse events and mortality, and recent studies point at the risk of developing a transient or persistent renal dysfunction. Patients with ST-elevation myocardial infarction treated by primary percutaneous coronary intervention have a markedly increased risk of developing CIN. At present no strategy is universally accepted in the prevention of CIN in the acute setting of primary percutaneous coronary intervention.
Method:
We performed a systematic search in Pubmed and EMBASE and ended up including nine randomised clinical trials; six studies of N-acetylcysteine, one study of early and late hydration regimens, one study of recombinant human brain natriuretic peptide and one study comparing a low-osmolar contrast agent with an iso-osmolar contrast agent.
Results:
Recombinant human brain natriuretic peptide and the regimens of hydration significantly reduced the incidence of CIN and administration of N-acetylcysteine in one of the six studies significantly reduced the occurrence of CIN. The iso-osmolar contrast agent was not proven to be superior to the low-osmolar contrast agent in terms of preventing CIN.
Conclusion:
Preliminary studies are promising but further studies are needed before any prevention strategy against CIN can be recommended in routine care of patients undergoing primary percutaneous coronary intervention for STEMI.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Related Concept Videos
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:26Cardiac Catheterization IV: Nursing Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:28Imaging Studies for Cardiovascular System V: CT
01:30Acute Coronary Syndrome I: Introduction
01:19Imaging Studies VII: Vascular Imaging